Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R2 | O00459 | 14/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6082191 | 0.89 | BTK (0.36) | PIK3R2KDM4EHSP90AA1L3MBTL1 | |
| SCHEMBL6081888 | 0.83 | MALT1 (0.41) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6083223 | 0.81 | PIK3R2 (0.40) | PIK3R2NR4A2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6082264 | 0.80 | SLC9A1 (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6082112 | 0.80 | CLK1 (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4240873 | 0.80 | PIK3R2 (0.47) | PIK3R2NR4A2 | |
| SCHEMBL6083534 | 0.80 | JAK2 (0.38) | NR4A2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6082339 | 0.80 | CDK8 (0.36) | PIK3R2KDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL6082306 | 0.79 | SLC9A1 (0.44) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6083001 | 0.77 | MALT1 (0.43) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078414-B2 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | claimed |
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-30 | — | — | US | claimed |
| US-7078414-B2 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-18 | — | — | US | disclosed |
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266775-A1 | Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions comprising them | GPBAR1, ADRB3, ADRA1A | PIK3R2 2464/4885NR4A2 1901/4885KDM4E 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.